VivoSeq
Cardiovascular

Transthyretin Amyloid Cardiomyopathy

8

Pipeline Programs↗

5

Active Trials↗

8

Companies Involved↗

Transthyretin Amyloid Cardiomyopathy is an early-stage landscape with 8 programs across 8 companies. The most active players are AstraZeneca, Alnylam Pharmaceuticals, Navire Pharma Inc., a BridgeBio company. 4 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 3Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

ApprovedN

Navire Pharma Inc., a BridgeBio company

1 program

ApprovedBoehringer Ingelheim logo

Boehringer Ingelheim

1 program

ApprovedK

K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

1 program

ApprovedPfizer logo

Pfizer

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

6 of 8 classified programs — the dominant modality here.

25%ALL OTHERSRNA therapy225%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed7 · 58%
Active, not recruiting2 · 17%
Recruiting2 · 17%
Not yet recruiting1 · 8%

Clinical Trials

Trial Activity

12 trials

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)
Recruiting·—·Phase 1/2·NCT06318260·35 enrolled
A Prospective, Single-arm, Phase 4 Study to Evaluate the Course of Serum Transthyretin (TTR) Level With Acoramidis in Adult Patients With Variant or Wild-type Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) Previously Treated With Tafamidis
Recruiting·Bayer logoBayer·Approved·NCT07298044·50 enrolled
Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy
Active, not recruiting·Pfizer logoPfizer·N/A·NCT04801329·110 enrolled
EPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
Active, not recruiting·AstraZeneca logoAstraZeneca·Phase 3·NCT06194825·64 enrolled
A Multicenter Pilot Study to Investigate Ocular Involvement and the Potential of Ocular Imaging for Non-invasive Screening for Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Not yet recruiting·AstraZeneca logoAstraZeneca·N/A·NCT07690436·500 enrolled
Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
Completed·Pfizer logoPfizer·N/A·NCT06393465·50 enrolled
A Study to Learn About the Study Medicine Called Tafamidis 61mg in People Diagnosed With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Completed·Pfizer logoPfizer·N/A·NCT06321523·13 enrolled
A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
Completed·Pfizer logoPfizer·N/A·NCT06086353·6 enrolled
SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy
Completed·—·Phase 4·NCT05233163·15 enrolled
A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Completed·Pfizer logoPfizer·Phase 4·NCT04814186·53 enrolled
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy
Completed·EEidos Therapeutics, a BridgeBio company·Phase 3·NCT03860935·632 enrolled
Doxycycline and TUDCA in Patients With Transthyretin Amyloid Cardiomyopathy
Completed·—·Phase 1/2·NCT01855360·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)